Skip to content Skip to footer
Subscribe Now
Viewpoints_Paul Brennan
VIEWPOINTS
PharmaShots Interview: NervGen’s Paul Brennan Shares Insights on NVG-291 and its Interim Data for the Treatment of Neurodegenerative Diseases
In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment of Neurodegenerative Diseases Shots: The P-I clinical trials evaluate NVG-291 vs PBO in healthy volunteers with neurodegenerative diseases such as AD and MS. The interim results were presented at ANA 146th annual meeting The interim…
November 17, 20210Comments
Viewpoints_Christopher J. Calhoun
VIEWPOINTS
PharmaShots Interview: Paracrine’s Christopher J. Calhoun Shares Insight on the First Autologous, Device-Based Cell Therapy Platform
In an interview with PharmaShots, Christopher J. Calhoun, President & CEO at Paracrine shared his views on the transforming diabetes treatment with the first autologous, device-based cell therapy platform Shots: The company has developed the first autologous, device-based cell therapy platform which is ideally positioned to address conditions with underlying integers Paracrine is a one-time, completely natural procedure that…
November 16, 20210Comments
Viewpoints_Jan van de Winkel
VIEWPOINTS
PharmaShots Interview: Genmab’s Jan van de Winkel Shares Insight on the Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer
In an interview with PharmaShots, Jan van de Winkel, co-founder, President, and CEO at Genmab shared his views on the US FDA's Accelerated Approval of Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer Shots: Genmab and Seagen have reported the US FDA's accelerated approval which is based on the P-II innovaTV 204 clinical trials evaluating tisotumab vedotin in…
November 15, 20210Comments
Viewpoints_Lloyd Miller
VIEWPOINTS
PharmaShots Interview: Janssen’s Lloyd Miller Shares Insight on the Data of Tremfya (guselkumab) Presented at EADV 2021
In an interview with PharmaShots, Lloyd Miller, MD, Ph.D., Vice President, Immunodermatology Disease Area Leader at Janssen shares his views on the data presented at EADV 2021 about patients who switch to Tremfya (guselkumab) from Humira (adalimumab) in P-III VOYAGE 1 & 2 trials for PsO & also highlighting the P-III DISCOVER-1 & 2 trial for PsA Shots: The P-III VOYAGE 1 &…
November 10, 20210Comments
Viewpoints_Garret Hampton
VIEWPOINTS
PharmaShots Interview: Thermo Fisher Scientific Garret Hampton Shares Insight on the Multiyear Agreement with AstraZeneca for NGS-based CDx
In an interview with PharmaShots, Garret Hampton, President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific share his views on multiyear agreement with AstraZeneca to co-develop NGS-based CDx for targeted therapies Shots: The collaboration will expand AstraZeneca’s portfolio of targeted therapies for cancer & other diseases. Thermo Fisher currently offers the NGS CDx solution which is approved…
November 9, 20210Comments
Viewpoints_Dr. Trevor Feinstein and Dr. Lan Huang
VIEWPOINTS
PharmaShots Interview: Dr. Trevor Feinstein and BeyondSpring’s Dr. Lan Huang Shares Insight on the Data of Plinabulin + Docetaxel for NSCLC with EGFR Wild Type
In an interview with PharmaShots, Dr. Trevor Feinstein (Hematology Specialist in Fayetteville, GA) and Dr. Lan Huang (Co-founder, Chairman, and CEO at BeyondSpring) shared their views on the data of Plinabulin + Docetaxel in P-III DUBLIN-3 trial for NSCLC with EGFR Wild Type Shots: The P-III DUBLIN-3 trial evaluates plinabulin + docetaxel vs docetaxel alone in 599 patients with 2L & 3L NSCLC EGFR wild type,…
November 8, 20210Comments
Viewpoints_Dr. Bob Cobuzzi
VIEWPOINTS
PharmaShots Interview: Diffusion’s Dr. Bob Cobuzzi Shares Insights on the Trans Sodium Crocetinate (TSC) to Improve Hypoxia
In an interview with PharmaShots, Dr. Bob Cobuzzi, CEO, President, and Board Member at Diffusion shared his views on the trans sodium crocetinate (TSC) to improve patient outcomes & paradigm of oxygen deprivation treatment Shots: Diffusion's TSC directly targets and relieves oxygen-deprivation in affected tissue by enhancing oxygen diffusion & was designed to treat hypoxia include trauma, heart attack, stroke,…
November 3, 20210Comments